Byondis Entered into a Multiple Agreement with medac to Commercialize Trastuzumab Duocarmazine (SYD985) for the Treatment of Cancer
Shots:
- Byondis to receive an up front & will also be eligible to receive an additional fee upon achievement of development and sales milestones along with sales royalties
- Under the terms of license, collaboration & supply agreement, medac gets an exclusive license to commercialize SYD985 in the EU, UK, and EU countries in all approved indications
- The results from the P-III (TULIP/SYD985.002) study of SYD985 in HER2-positive unresectable LA or metastatic breast cancer showed a significant PFS & the company plans to submit SYD985’ MAA to the EMA shortly. The therapy is also being evaluated in a P-II trial for HER2-expressing recurrent, advanced or metastatic endometrial cancer
Ref: PRNewswire | Image: Byondis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
